Effect of levamisole on skin reactions to DNCB in chronically dialyzed patients

The local cutaneous inflammatory response to DMCB sensitization was positive in only 35% of 20 uremic patients, and the delayed skin reaction was positive in only 15%. The reaction to DMCB challenge was markedly delayed in some patients. Improved response to DNCB re-challenge followed levamisole administration in only 16% of the patients and was not associated with a rise in blood lymphocytes.